GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LumiraDx Ltd (OTCPK:LMDXF) » Definitions » Capex-to-Operating-Income

LumiraDx (LumiraDx) Capex-to-Operating-Income : 0.00 (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is LumiraDx Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

LumiraDx's Capital Expenditure for the three months ended in Jun. 2023 was $-0.82 Mil. Its Operating Income for the three months ended in Jun. 2023 was $-48.43 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


LumiraDx Capex-to-Operating-Income Historical Data

The historical data trend for LumiraDx's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LumiraDx Capex-to-Operating-Income Chart

LumiraDx Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Capex-to-Operating-Income
- - - -

LumiraDx Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of LumiraDx's Capex-to-Operating-Income

For the Diagnostics & Research subindustry, LumiraDx's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LumiraDx's Capex-to-Operating-Income Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, LumiraDx's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where LumiraDx's Capex-to-Operating-Income falls into.



LumiraDx Capex-to-Operating-Income Calculation

LumiraDx's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-24.983) / -322.624
=N/A

LumiraDx's Capex-to-Operating-Income for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.821) / -48.43
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LumiraDx  (OTCPK:LMDXF) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


LumiraDx Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of LumiraDx's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


LumiraDx (LumiraDx) Business Description

Traded in Other Exchanges
N/A
Address
C/o Ocorian Trust (Cayman) Ltd, Windward 3, P.O. Box 1350, Regatta Office Park, Grand Cayman, CYM, KY1-1108
LumiraDx Ltd is a next-generation point of care diagnostics company. It manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. Geographical presence in United States, Italy, UK, Germany, Colombia, Sweden and Other countries. Majority revenue derives from U.S.